The central stimulant and potential antiparkinsonism effects of 2(p-nitrobenzylthio)-imidazoline (3H)-HCl.
D000818:Animals; D000978:Antiparkinson Agents / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects; D001831:Body Temperature / Q000187:drug effects; D001923:Brain Chemistry / Q000187:drug effects; D002247:Carbon Isotopes; D002421:Caudate Nucleus / Q000378:metabolism; D004298:Dopamine / Q000032:analysis / Q000378:metabolism; D004347:Drug Interactions; D005260:Female; D000882:Haplorhini; D007031:Hypothalamus / Q000378:metabolism; D007093:Imidazoles / Q000494:pharmacology*; D008251:Macaca; D051379:Mice; D008815:Mice, Inbred Strains; D009043:Motor Activity / Q000187:drug effects; D009578:Nitrobenzenes / Q000494:pharmacology*; D009638:Norepinephrine / Q000032:analysis / Q000378:metabolism; D010300:Parkinson Disease / Q000188:drug therapy*; D010424:Pentobarbital / Q000494:pharmacology; D051381:Rats; D012701:Serotonin / Q000032:analysis; D013440:Sulfides / Q000494:pharmacology
D000978:Antiparkinson Agents; D002247:Carbon Isotopes; D007093:Imidazoles; D009578:Nitrobenzenes; D013440:Sulfides; D012701:Serotonin; D010424:Pentobarbital; D004298:Dopamine; D009638:Norepinephrine